Edap Tms SaFOCL

NasdaqHealthcareElectromedical & Electrotherapeutic Apparatus
Price (close)
$4.59
Market cap
$216.7M
P/E
—
Revenue (FY)
—
Net income
—
Dividend yield
—
1-year total return
82.1%
Net margin
—
Revenue growth
—
Debt / equity
—

What Edap Tms Sa does.

EDAP TMS S.A. (“EDAP,” the “Company,” “we,” “us,” or “our”) is a medical technology company focused on the development, manufacturing, marketing, and sale of non-invasive therapeutic ultrasound and energy-based medical devices.

Our legal name is EDAP TMS S.A., and our commercial name is Focal One ® . We were founded in 1979 as a société anonyme organized under the laws of France for a duration of 60 years from the date of incorporation, unless extended by shareholder approval in accordance with French corporate law. We are headquartered in Vaulx-en-Velin, France and operate in the United States, Europe, Asia and the rest of the world. We are listed on The Nasdaq Global Market (“Nasdaq”) under the symbol “EDAP.”

Our technologies are primarily used in urology, with a current focus on the treatment of prostate cancer. We are conducting clinical development activities to support potential expanded indications in urology and women’s health.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$41.7M$44.1M$55.1M$60.4M$64.1M—
Net income-$1.7M$699,890-$2.9M-$21.2M-$19.0M—
Free cash flow——————

More on FOCL.

Figures from Edap Tms Sa's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.